Board of Directors


  • Jonathan M. Peacock
    Chairman


    Jonathan Peacock serves as the Chairman of our Board of Directors. Previously, Mr. Peacock served as both President and Chief Executive Officer as well as Chairman of our Board of Directors. Prior to joining us, Mr. Peacock served as the Chief Financial Officer of Amgen from August 2010 to January 2014. From 2005 to 2010, he served as Chief Financial and Administrative Officer of Novartis Pharmaceuticals AG, the Pharmaceutical and Biotechnology Division of Novartis AG. Mr. Peacock was also a partner at McKinsey and Co, the strategy consulting firm from 1998 to 2005 and a partner at Price Waterhouse from 1993 to 1998. Mr. Peacock received an M.A. degree in economics from the University of St. Andrews.

  • Fabian Tenenbaum
    Chief Executive Officer


    Mr. Tenenbaum serves as our Chief Executive Officer. Previously, Mr. Tenenbaum served as our Chief Financial Officer and Chief Business Officer. Prior to joining Bellerophon, Mr. Tenenbaum served as Chief Financial Officer and Chief Business Officer of Anterios, Inc., a clinical-stage biopharmaceutical company, from 2014 to 2016. Prior to that, Mr. Tenenbaum served as Chief Executive Officer with Syneron Beauty from 2011 to 2014, and Chief Financial Officer and Executive Vice President of Syneron Medical from 2007 to 2011. Prior to Syneron Medical, Mr. Tenenbaum was Vice President Americas for Radiancy, Inc., from 2002 to 2006, and Director, Commercial Operations and Corporate Development at Sunlight Medical, Inc. from 1999 to 2002. Mr. Tenenbaum holds a Bachelor in Medicine (B.Md.) from Ben Gurion University, Israel and an MBA from Columbia Business School.

  • Naseem Amin, M.D.
    Director


    Naseem Amin has broad industry experience in the Biotech and Medical Device industry and served as the Chief Scientific Officer of Smith and Nephew Plc until 2014. Previously, Dr. Amin was Senior Vice President, Business Development at Biogen Idec from 2005 to 2009 and was with Genzyme Corporation from 1999 to 2005, most recently as Head, International Business Development and where he has also led the clinical development of five currently marketed therapeutic products. Dr. Amin began his career at Baxter Healthcare Corporation, where he served as Director, Medical Marketing and Portfolio Strategy, Renal Division. Dr. Amin is a Venture Partner at Advent Life Sciences, serves as an Advisory Board member for Imperial College, Department of Biomedical Engineering, and serves as Chairman of OPEN-London, a non-profit organization focused on encouraging and mentoring South Asians from Pakistan who are interested in starting entrepreneurial companies. Dr. Amin received his medical degree from the Royal Free School of Medicine, London, and an MBA from the Kellogg Graduate School of Management, Northwestern University.

  • Matthew M. Bennett
    Director


    Matthew M. Bennett serves as a Managing Director of New Mountain Capital, LLC (“ NMC ”), and he joined that organization in 2007. Mr. Bennett serves on the board of directors of CIOX Health, Gelest, Cytel and Alteon Health and also works closely with other NMC companies. Mr. Bennett previously served as Chief Executive Officer of CIOX Health and before that, he served as Executive Vice President, Global Medical Operations and Chief Legal Officer for Ikaria, Inc. (“ Ikaria ”), where he served in additional executive roles, including Chief Financial Officer and head of Corporate Development. Prior to joining Ikaria, Mr. Bennett served as Exe utive Vice President, Chief Administrative Officer, and Chief Business Officer at VIASYS Healthcare, Inc. (NYSE: VAS) (“ VIASYS ”), where he was responsible for the company’s growth and mergers and acquisitions. Prior to VIASYS, Mr. Bennett served as an advisor on mergers and acquisitions, initial public offerings, and commercial transactions in the health care field at Morgan, Lewis & Bockius LLP, and a litigator in the health care area at Stradley, Ronon, Stevens & Young. Mr. Bennett holds an A.B. in Political Science from Princeton University and a J.D. from Villanova University School of Law.

  • Scott P. Bruder, M.D., Ph.D.
    Director


    Scott Bruder currently leads Bruder Consulting International with a global team that provides scientific, clinical, regulatory and development strategy services to medical device, regenerative medicine and biotechnology companies, investment banks, venture partners and private equity firms. He is also an adjunct Professor of Biomedical Engineering at Case Western Reserve University, where he previously served as an adjunct faculty member in the Department of Orthopaedic Surgery for thirteen years. Dr Bruder currently serves as the Chairman of the Board of Directors of Amendia, a privately held, leading provider of innovative medical devices used during spinal surgery procedures. Dr Bruder served as the Chief Medical and Scientific Officer of Stryker Corporation from 2012 until 2014, and was the Chief Scientific and Technology Officer for Becton, Dickinson and Company from 2007 until 2012. Previously, Dr. Bruder held a number of senior executive and scientific roles at Johnson & Johnson, Anika Therapeutics and Osiris Therapeutics. Dr. Bruder is a magna cum laude graduate from Brown University with a Sc.B. in Biology, and a graduate of Case Western Reserve University School of Medicine, where he simultaneously earned an M.D. and a Ph.D. in stem cell biology.

  • Mary Ann Cloyd
    Director


    Mary Ann Cloyd was a Senior Partner with PricewaterhouseCoopers (PwC) with responsibility for leading PwC’s Center for Board Governance at the time of her retirement in 2015. Ms. Cloyd has over 39 years of public accounting experience serving multinational corporate clients in a variety of industries including biotechnology and pharmaceuticals. Ms. Cloyd has served on both PwC’s Global and US Boards, where she chaired the Risk Management, Ethics & Compliance Committee and the Partner Admissions Committee on the US Board. On the Global Board, she served on the Risk and Operations Committee and the Clients Committee. Ms. Cloyd is on the Board of Trustees of the PricewaterhouseCoopers Charitable Foundation, Inc. and a past President of the Foundation, and she is Chair of the UCLA Iris Cantor Women’s Center Advisory Board. Ms. Cloyd graduated Summa Cum Laude from Baylor University with a Bachelor of Business Administration.

  • Andre V. Moura
    Director


    Andre V. Moura is a Director at New Mountain Capital. Prior to joining New Mountain Capital in 2005, Mr. Moura was employed by McKinsey & Company. Mr. Moura also serves on the board of directors of three privately held companies. Mr. Moura received an A.B. in computer science from Harvard College and an M.B.A. from Harvard Business School.

  • Crispin Teufel
    Director


    Crispin Teufel has served as the Chief Executive Officer of Lincare Holdings Inc., the leading national provider of respiratory services in the home, since 2017 and as its Chief Financial Officer since 2013. Previously, he served as Finance Director for Linde Engineering in Germany from 2011-2013. Prior to joining Linde, Mr. Teufel held various financial positions at PWC and Arthur Andersen. Mr. Teufel serves on the board of directors of the German-American Chamber of Commerce and served on the IFRS Committee of the Accounting Standards Committee of Germany from 2011-2013. Mr. Teufel holds an MBA in Economics from Ruhr University Bochum, Germany, is a Certified Public Accountant and is a German Tax Advisor under Germany’s Taxation and Ministry of Finance.

  • Dr. Ted Wang
    Director


    Dr. Wang has served as the Chief Investment Officer of Puissance Capital Management LP, of which he was a founder, since January 2015. Prior to that, Dr. Wang was a Partner of Goldman, Sachs & Co. (“Goldman”), which he joined in 1996 and with which he served in many leadership positions, mostly recently as Co-Head of U.S. Equities Trading and Global Co-Head of One Delta Trading and a member of the Goldman Sachs Risk Committee. Prior to joining Goldman, Dr. Wang co-founded Xeotron Corp., a company specializing in DNA biochips in Texas. Dr. Wang holds a Ph.D. in Physics from the University of Minnesota, an M.B.A. from the University of Texas, Austin, and a B.S. from Fudan University, China.